Evidence map›Paper›PMID 28441013›Full record

ArticleInorganic chemistry2017

Cytotoxicity of Pyrazine-Based Cyclometalated (C^N

Benoît Bertrand, Julio Fernandez-Cestau, Jesus Angulo, Marco M D Cominetti, Zoë A E Waller, Mark Searcey, Maria A O'Connell, Manfred Bochmann

Open access · greenAbstract read
In one paragraph

Article in Inorganic chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 65 citations in OpenAlex.

  1. TheBeilstein journal of organic chemistry · 2026
    Article
  2. Review
  3. Current Developments ofBiomedicines · 2022
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Angewandte Chemie (International ed. in English) · 2020
    Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Benoît BertrandSchool of Chemistry, University of East Anglia , Norwich NR4 7TJ, United Kingdom.ORCID http://orcid.org/0000-0003-0542-4454
Julio Fernandez-CestauSchool of Chemistry, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Jesus AnguloSchool of Pharmacy, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Marco M D CominettiSchool of Pharmacy, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Zoë A E WallerSchool of Pharmacy, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Mark SearceySchool of Chemistry, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Maria A O'ConnellSchool of Pharmacy, University of East Anglia , Norwich NR4 7TJ, United Kingdom.
Manfred BochmannSchool of Chemistry, University of East Anglia , Norwich NR4 7TJ, United Kingdom.ORCID http://orcid.org/0000-0001-7736-5428
University of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synthesis of a series of cyclometalated gold(III) complexes supported by pyrazine-based (C^N^C)-type pincer ligands is reported, including the crystal structure of a cationic example. The compounds provide a new platform for the study of antiproliferative properties of gold(III) complexes. Seven complexes were tested: the neutral series (C^N

Indexed as

Antineoplastic AgentsCell Line, TumorCell ProliferationCrystallography, X-RayDose-Response Relationship, DrugDrug Screening Assays, AntitumorFluorescence PolarizationHumansLigandsMethaneModels, MolecularMolecular StructureOrganogold CompoundsPyrazinesStructure-Activity RelationshipAntineoplastic AgentscarbeneLigandsMethaneOrganogold CompoundsPyrazines

Identifiers

PMID28441013
PMCPMC5434479
OpenAlexW2609662172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.